Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 83

Sort by

Sort Order Select

Journal Articles

Mutations and Copy Number Gains of the BCL2 Family Members Mediate Resistance to Venetoclax in Multiple Myeloma (MM) Patients

Paola Neri, MD PhD, Ranjan Maity, PhD, Jean-Baptiste Alberge, Sarthak Sinha, BSc, Justin Donovan, Madison Kong, Fajer Hasan, Arzina Jaffer, Lawrence H. Boise, PhD, Nizar Bahlis, MD

Blood (2019) 134 (Supplement_1): 572.

https://doi.org/10.1182/blood-2019-127593

Published: 2019

Journal Articles

Functional Characterization of E3 Ligases and Their Regulators: Therapeutic Implications for Development of New Proteolysis-Targeting Chimeric Degraders of Oncoproteins

Blood (2019) 134 (Supplement_1): 318.

https://doi.org/10.1182/blood-2019-130549

Published: 2019

Journal Articles

Statins Enhance Killing of Multiple Myeloma Cells By the BCL-2 Inhibitor Venetoclax and the MCL-1 Inhibitor S63845

David Fruman, PhD, Dennis Juarez, B.S., Grace Diep, Undergraduate, Falisha Nguyen, Undergraduate, Vikas A. Gupta, MD PhD, Lawrence H. Boise, PhD

Blood (2019) 134 (Supplement_1): 4413.

https://doi.org/10.1182/blood-2019-131218

Published: 2019

Journal Articles

Systematic Characterization of Genes Representing Preferential Molecular Vulnerabilities for Myeloma Cells Compared to Other Neoplasias - Implications for the Biology and Therapeutic Targeting of Myeloma

Blood (2019) 134 (Supplement_1): 4407.

https://doi.org/10.1182/blood-2019-130901

Published: 2019

Journal Articles

The Role of Proteasome Activator PA28α in Multiple Myeloma

Yanyan Gu, MD PhD, Benjamin G Barwick, PhD, Mala Shanmugam, PhD, Craig C Hofmeister, MDMPH, Jonathan L. Kaufman, MD, Ajay K Nooka, MDMPH, Vikas A. Gupta, MD PhD, Madhav V Dhodapkar, MBBS, Lawrence H. Boise, PhD, Sagar Lonial

Blood (2019) 134 (Supplement_1): 5499.

https://doi.org/10.1182/blood-2019-128216

Published: 2019

Journal Articles

Multiple Myeloma Epigenetic Programming Prognostic of Outcome Converges with Loci Reprogrammed in Relapsed/Refractory Disease

Benjamin G Barwick, PhD, Sheri Skerget, PhD, Jonathan J Keats, PhD, Daniel Auclair, Sagar Lonial, Lawrence H. Boise, PhD, Paula M Vertino, PhD, Doris R Powell, MA

Blood (2019) 134 (Supplement_1): 858.

https://doi.org/10.1182/blood-2019-124422

Published: 2019

Journal Articles

Phase I/II Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Dexamethasone As Targeted Therapy for Patients with t(11;14) Relapsed/Refractory Multiple Myeloma

Jonathan L. Kaufman, MD, Cristina Gasparetto, MD, Fredrik H. Schjesvold, MD PhD, Philippe Moreau, MD, Cyrille Touzeau, MD, Thierry Facon, MD, Lawrence H. Boise, PhD, Stefanie Alzate, MSc, Tammy Macartney, John Pesko, PhD, Ahmed Hamed Salem, PhD FCP, Jeremy A. Ross, PhD, Wan-Jen Hong, MD, Paulo C. Maciag, MD PhD, James M. Pauff, MD PhD, Shaji K. Kumar, MD

Blood (2019) 134 (Supplement_1): 926.

https://doi.org/10.1182/blood-2019-125871

Published: 2019

Journal Articles

Outcomes of Myeloma Patients with Deletion 1p Receiving Lenalidomide, Bortezomib, and Dexamethasone (RVD) Therapy

Levani Odikadze, MD MPH, Nisha Joseph, MD, Timothy M. Schmidt, MD, Leonard Heffner, MD, Craig C Hofmeister, MD MPH, Madhav V Dhodapkar, MD, Vikas A. Gupta, MD PhD, Lawrence H. Boise, PhD, David L. Jaye, MD, Sagar Lonial, MD, Ajay K Nooka, MD MPH, Jonathan L Kaufman, MD

Blood (2018) 132 (Supplement 1): 1884.

https://doi.org/10.1182/blood-2018-99-114368

Published: 2018

Journal Articles

Myeloma Patient-Derived MCL1 Point Mutations Can Influence MCL1-Inhibitor Function

Brandon Chen, Wong Pamela, B.S., Daniel Auclair, PhD, Jonathan J Keats, PhD, Paul Secrist, PhD, Justin Cidado, PhD, Adriana E. Tron, PhD, Christine M Dunham, PhD, Sagar Lonial, MD, Joseph Opferman, PhD, Shannon M Matulis, PhD, Lawrence H. Boise, PhD

Blood (2018) 132 (Supplement 1): 951.

https://doi.org/10.1182/blood-2018-99-113444

Published: 2018

Journal Articles

Preclinical Activity of Novel MCL1 Inhibitor AZD5991 in Multiple Myeloma

Shannon M Matulis, PhD, Vikas A. Gupta, MD PhD, Izabelle Brown, Jonathan J Keats, PhD, Paul Secrist, PhD, Justin Cidado, PhD, Adriana E. Tron, PhD, Paola Neri, MD, Nizar Bahlis, MD, Jonathan L Kaufman, MD, Leonard Heffner, MD, Sagar Lonial, MD, Ajay K Nooka, MDMPH, Lawrence H. Boise, PhD

Blood (2018) 132 (Supplement 1): 952.

https://doi.org/10.1182/blood-2018-99-113504

Published: 2018

Journal Articles

Immunoglobulin Lambda Translocations Identify Poor Outcome and IMiD Resistance in Multiple Myeloma and Co-Occur with Hyperdiploidy

Benjamin G Barwick, PhD, Paola Neri, MD, Nizar Bahlis, MD, Ajay K Nooka, MDMPH, Jonathan L Kaufman, MD, Vikas A. Gupta, MD PhD, Daniel Auclair, PhD, Jonathan J Keats, PhD, Sagar Lonial, MD, Paula M Vertino, PhD, Lawrence H. Boise, PhD

Blood (2018) 132 (Supplement 1): 405.

https://doi.org/10.1182/blood-2018-99-113585

Published: 2018

Journal Articles

Outcomes of Myeloma Patients with t(11;14) Receiving Lenalidomide, Bortezomib, and Dexamethasone (RVD) Induction Therapy

Jonathan L Kaufman, MD, Nisha Joseph, MD, Vikas A. Gupta, MD PhD, Charise Gleason, ANP, Craig C Hofmeister, MD MPH, Leonard Heffner, MD, Madhav V Dhodapkar, MD, Sagar Lonial, MD, Lawrence H. Boise, PhD, Ajay K Nooka, MD MPH

Blood (2018) 132 (Supplement 1): 3282.

https://doi.org/10.1182/blood-2018-99-119051

Published: 2018

Journal Articles

Outcomes and Clinical Features of Patients with 1q+ Multiple Myeloma Treated with Lenalidomide, Bortezomib, and Dexamethasone

Timothy M. Schmidt, MD, Nisha Joseph, MD, Levani Odikadze, MD MPH, Leonard Heffner, MD, Craig C Hofmeister, MD MPH, Madhav V Dhodapkar, MD, Vikas A. Gupta, MD PhD, Lawrence H. Boise, PhD, David L. Jaye, MD, Sagar Lonial, MD, Ajay K Nooka, MD MPH, Jonathan L Kaufman, MD

Blood (2018) 132 (Supplement 1): 3241.

https://doi.org/10.1182/blood-2018-99-112216

Published: 2018

Journal Articles

Efficacy of Induction Thearapy with Lenalidomide, Bortezomib, and Dexamethasone (RVD) in 1000 Newly Diagnosed Multiple Myeloma (MM) Patients

Nisha Joseph, MD, Vikas A. Gupta, MD PhD, Craig C Hofmeister, MD MPH, Charise Gleason, ANP, Leonard Heffner, MD, Lawrence H. Boise, PhD, Jonathan L Kaufman, MD, Madhav V Dhodapkar, MD, Sagar Lonial, MD, Ajay K Nooka, MD MPH

Blood (2018) 132 (Supplement 1): 3294.

https://doi.org/10.1182/blood-2018-99-119895

Published: 2018

Journal Articles

Impact of Early Progression on Long Term Outcomes Among Myeloma Patients Receiving Lenalidomide, Bortezomib, and Dexamethasone (RVD) Induction Therapy

Ajay K Nooka, MDMPH, Jonathan L Kaufman, MD, Charise Gleason, ANP, Nisha Joseph, MD, Craig C Hofmeister, MD MPH, Lawrence H. Boise, PhD, Leonard Heffner, MD, Madhav V Dhodapkar, MD, Sagar Lonial, MD

Blood (2018) 132 (Supplement 1): 3302.

https://doi.org/10.1182/blood-2018-99-120314

Published: 2018

Journal Articles

Differences in Presentation and Survival Outcomes for African American Patients with Newly Diagnosed Multiple Myeloma

Blood (2018) 132 (Supplement 1): 5647.

https://doi.org/10.1182/blood-2018-99-119948

Published: 2018

Journal Articles

Whole Genome DNA Methylation Analysis of Commpass Identifies Biomarkers of Multiple Myeloma Survival

Benjamin G Barwick, PhD, Daniel Auclair, PhD, Alex Blanski, Meghan Kirchhoff, Brianne Docter, Daniel C Rohrer, Jonathan J Keats, PhD, Sagar Lonial, MD, Lawrence H. Boise, PhD, Paula M Vertino, PhD

Blood (2018) 132 (Supplement 1): 3174.

https://doi.org/10.1182/blood-2018-99-116875

Published: 2018

Journal Articles

A Role for Syntenin-1 in Multiple Myeloma Cell Survival

Tyler Moser-Katz, Catherine M. Gavile, Benjamin G Barwick, PhD, Sagar Lonial, MD, Lawrence H. Boise, PhD

Blood (2018) 132 (Supplement 1): 1008.

https://doi.org/10.1182/blood-2018-99-113594

Published: 2018

Journal Articles

CRISPR-Based Functional Genomics Studies Reveal Distinct and Overlapping Genes Mediating Resistance to Different Classes of Heterobifunctional Degraders of Oncoproteins: Implications for Novel Therapeutics across Diverse Neoplasias

Blood (2018) 132 (Supplement 1): 1367.

https://doi.org/10.1182/blood-2018-99-116232

Published: 2018

Journal Articles

Single Cell Resolution Profiling Defines the Innate and Adaptive Immune Repertoires Modulated By Daratumumab and IMiDs Treatment in Multiple Myeloma (MM)

Paola Neri, MD, Ranjan Maity, PhD, Ines Tagoug, PhD, Peter Duggan, MD FRCPC, Sylvia McCulloch, MD, Victor Jimenez-Zepeda, MD, Jason Tay, MD FRCPC, Lawrence H. Boise, PhD, Anjan Thakurta, PhD, Nizar J. Bahlis, MD

Blood (2017) 130 (Supplement 1): 123.

https://doi.org/10.1182/blood.V130.Suppl_1.123.123

Published: 2017

NARROW

Mutations and Copy Number Gains of the BCL2 Family Members Mediate Resistance to Venetoclax in Multiple Myeloma (MM) Patients

Functional Characterization of E3 Ligases and Their Regulators: Therapeutic Implications for Development of New Proteolysis-Targeting Chimeric Degraders of Oncoproteins

Statins Enhance Killing of Multiple Myeloma Cells By the BCL-2 Inhibitor Venetoclax and the MCL-1 Inhibitor S63845

Systematic Characterization of Genes Representing Preferential Molecular Vulnerabilities for Myeloma Cells Compared to Other Neoplasias - Implications for the Biology and Therapeutic Targeting of Myeloma

The Role of Proteasome Activator PA28α in Multiple Myeloma

Multiple Myeloma Epigenetic Programming Prognostic of Outcome Converges with Loci Reprogrammed in Relapsed/Refractory Disease

Phase I/II Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Dexamethasone As Targeted Therapy for Patients with t(11;14) Relapsed/Refractory Multiple Myeloma

Outcomes of Myeloma Patients with Deletion 1p Receiving Lenalidomide, Bortezomib, and Dexamethasone (RVD) Therapy

Myeloma Patient-Derived MCL1 Point Mutations Can Influence MCL1-Inhibitor Function

Preclinical Activity of Novel MCL1 Inhibitor AZD5991 in Multiple Myeloma

Immunoglobulin Lambda Translocations Identify Poor Outcome and IMiD Resistance in Multiple Myeloma and Co-Occur with Hyperdiploidy

Outcomes of Myeloma Patients with t(11;14) Receiving Lenalidomide, Bortezomib, and Dexamethasone (RVD) Induction Therapy

Outcomes and Clinical Features of Patients with 1q+ Multiple Myeloma Treated with Lenalidomide, Bortezomib, and Dexamethasone

Efficacy of Induction Thearapy with Lenalidomide, Bortezomib, and Dexamethasone (RVD) in 1000 Newly Diagnosed Multiple Myeloma (MM) Patients

Impact of Early Progression on Long Term Outcomes Among Myeloma Patients Receiving Lenalidomide, Bortezomib, and Dexamethasone (RVD) Induction Therapy

Differences in Presentation and Survival Outcomes for African American Patients with Newly Diagnosed Multiple Myeloma

Whole Genome DNA Methylation Analysis of Commpass Identifies Biomarkers of Multiple Myeloma Survival

A Role for Syntenin-1 in Multiple Myeloma Cell Survival

CRISPR-Based Functional Genomics Studies Reveal Distinct and Overlapping Genes Mediating Resistance to Different Classes of Heterobifunctional Degraders of Oncoproteins: Implications for Novel Therapeutics across Diverse Neoplasias

Single Cell Resolution Profiling Defines the Innate and Adaptive Immune Repertoires Modulated By Daratumumab and IMiDs Treatment in Multiple Myeloma (MM)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only